Literature DB >> 22382052

A DRD2 and ANKK1 haplotype is associated with nicotine dependence.

Joanne Voisey1, Christopher Dean Swagell, Ian Paul Hughes, Angela van Daal, Ernest Pascal Noble, Bruce Robert Lawford, Ross McDonald Young, Charles Phillip Morris.   

Abstract

To test the importance of the dopamine D2 receptor (DRD2) region in nicotine dependence, 150 smokers and 228 controls were genotyped for the DRD2 C957T, -141delC and ANKK1 TaqIA polymorphisms (rs6277, rs1799732 and rs1800497, respectively). The -141delC SNP did not show any association but both the C957T and TaqIA SNPs showed association at the allele, genotype, haplotype and combined genotype levels. The 957C/TaqI A1 haplotype was more than 3.5 times as likely to be associated with nicotine dependence compared with the 957T/TaqI A1 haplotype (P=0.003). Analysis of the combined genotypes of both SNPs revealed that individuals who were homozygous for the 957C-allele (CC) and had either one or two copies of the TaqI A1-allele were 3.3 times as likely to have nicotine dependence compared to all other genotype combinations (P=0.0003) and that these genotypes accounted for approximately 13% of the susceptibility to nicotine addiction in our population. Our findings suggest that the DRD2 C957T polymorphism and the ANKK1 TaqIA polymorphism are key contributors to the genetic susceptibility to nicotine dependence.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22382052     DOI: 10.1016/j.psychres.2011.09.024

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  24 in total

Review 1.  Exercise as a novel treatment for drug addiction: a neurobiological and stage-dependent hypothesis.

Authors:  Wendy J Lynch; Alexis B Peterson; Victoria Sanchez; Jean Abel; Mark A Smith
Journal:  Neurosci Biobehav Rev       Date:  2013-06-24       Impact factor: 8.989

2.  Dopaminergic pathway polymorphisms and heroin addiction: further support for association of CSNK1E variants.

Authors:  Orna Levran; Einat Peles; Matthew Randesi; Joel Correa da Rosa; Jurg Ott; John Rotrosen; Miriam Adelson; Mary Jeanne Kreek
Journal:  Pharmacogenomics       Date:  2014-12       Impact factor: 2.533

3.  Updated findings of the association and functional studies of DRD2/ANKK1 variants with addictions.

Authors:  Yunlong Ma; Wenji Yuan; Xianzhong Jiang; Wen-Yan Cui; Ming D Li
Journal:  Mol Neurobiol       Date:  2014-08-20       Impact factor: 5.590

4.  Effects of OPRM1 and DRD2 on brain structure in drug-naïve adolescents: Genetic and neural vulnerabilities to substance use.

Authors:  Giorgia Picci; Diana H Fishbein; John W VanMeter; Emma J Rose
Journal:  Psychopharmacology (Berl)       Date:  2021-11-24       Impact factor: 4.530

5.  A variant in ANKK1 modulates acute subjective effects of cocaine: a preliminary study.

Authors:  C J Spellicy; M J Harding; S C Hamon; J J Mahoney; J A Reyes; T R Kosten; T F Newton; R De La Garza; D A Nielsen
Journal:  Genes Brain Behav       Date:  2014-03-17       Impact factor: 3.449

6.  DRD2 C957T polymorphism is associated with improved 6-month verbal learning following traumatic brain injury.

Authors:  John K Yue; Ethan A Winkler; Jonathan W Rick; John F Burke; Thomas W McAllister; Sam S Oh; Esteban G Burchard; Donglei Hu; Jonathan Rosand; Nancy R Temkin; Frederick K Korley; Marco D Sorani; Adam R Ferguson; Hester F Lingsma; Sourabh Sharma; Caitlin K Robinson; Esther L Yuh; Phiroz E Tarapore; Kevin K W Wang; Ava M Puccio; Pratik Mukherjee; Ramon Diaz-Arrastia; Wayne A Gordon; Alex B Valadka; David O Okonkwo; Geoffrey T Manley
Journal:  Neurogenetics       Date:  2016-11-08       Impact factor: 2.660

7.  Genetic influences on delay discounting in smokers: examination of a priori candidates and exploration of dopamine-related haplotypes.

Authors:  James MacKillop; Joshua C Gray; L Cinnamon Bidwell; Warren K Bickel; Christine E Sheffer; John E McGeary
Journal:  Psychopharmacology (Berl)       Date:  2015-07-29       Impact factor: 4.530

8.  ANKK1 and DRD2 pharmacogenetics of disulfiram treatment for cocaine abuse.

Authors:  Catherine J Spellicy; Thomas R Kosten; Sara C Hamon; Mark J Harding; David A Nielsen
Journal:  Pharmacogenet Genomics       Date:  2013-07       Impact factor: 2.089

9.  A pilot study of genetic variants in dopamine regulators with indoor tanning and melanoma.

Authors:  Kristina G Flores; Esther Erdei; Li Luo; Kirsten A M White; Shuguang Leng; Marianne Berwick; DeAnn Lazovich
Journal:  Exp Dermatol       Date:  2013-09       Impact factor: 3.960

10.  Impact of the DRD2 Polymorphisms on the Effectiveness of the Training Program.

Authors:  Katarzyna Świtała; Aleksandra Bojarczuk; Jacek Hajto; Marcin Piechota; Maciej Buryta; Agata Leońska-Duniec
Journal:  Int J Environ Res Public Health       Date:  2022-04-19       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.